Table 3:

Prior authorization outcome based on medication class, diagnostic order, and insurance type

Medication Class or Diagnostic Order	Initial approval (n = 25) n (%)	Initial denial (n = 26) n (%)
Topicals (tacrolimus ointment, pimecrolimus, clobetasol, fluocinolone, triamcinolone)	18 (86)	3 (14)
Immunosuppressives (mycophenolate/methotrexate/azathioprine)	3 (20)	12 (80)
Biologics (tofacitinib, omalizumab, secukinumab)/Lenalidomide	0 (0)	6 (100)
Imaging	4 (44)	5 (55)
Insurance Type
Public (Medicare/Medicaid)	10 (53)	9 (47)
Commercial	15 (47)	17 (53)